Memgen

Memgen is a clinical-stage biopharmaceutical company developing cancer immunotherapies that harness the power of the immune system to treat cancer. The company’s pipeline products all utilize its proprietary CD40L transgene, MEM40, which has been tested in clinical trials and has demonstrated the ability to elicit robust antigen-specific immune responses. Memgen's COVID-19 vaccine, MemVax, is an adjuvant designed to be used in conjunction with other COVID-19 vaccines to generate strong, long-lasting immune responses. MemVax is a specific immune stimulant that can be used with COVID-19 antigens through various delivery methods.